17th week of 2022 patent applcation highlights part 24 |
Patent application number | Title | Published |
20220127263 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates - The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD). | 2022-04-28 |
20220127264 | SUBSTITUTED PYRROLIDINE AMIDES II - The invention relates to compounds according to general formula (I), | 2022-04-28 |
20220127265 | THERAPEUTIC COMPOUNDS AND USES THEREOF - The present invention relates to a compound formula (I): | 2022-04-28 |
20220127266 | MALIC ENZYME INHIBITORS - The present invention relates to novel compounds useful as malic enzyme (ME) inhibitors, processes for their preparation and use of these compounds for the therapeutic treatment of disorders mediated by ME such as cancers (e.g. pancreatic ductal adenocarcinoma (PDAC)) in humans. | 2022-04-28 |
20220127267 | THIENO[3,2-B] PYRROLE[3,2-D]PYRIDAZINONE DERIVATIVES AND THEIR USE AS PKM2 DERIVATIVES FOR THE TREATMENT OF CANCER, OBESITY AND DIABETES RELATED DISORDERS - Described herein are compounds that regulate pyruvate kinase activity, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I) wherein R | 2022-04-28 |
20220127268 | SOLID STATE FORMS OF LUMATEPERONE DITOSYLATE SALT - Disclosed are solid state forms of lumateperone ditosylate, uses thereof, and pharmaceutical compositions thereof. | 2022-04-28 |
20220127269 | HETEROCYCLIC NITROGEN-CONTAINING PURINE DERIVATIVES, PHARMACEUTICAL PREPARATIONS CONTAINING THESE DERIVATIVES AND THEIR USE IN NEUROPROTECTION - Heterocyclic nitrogen-containing purine derivatives and their use in the medicinal applications and compositions containing these derivatives is disclosed. A new generation of compounds possessing selective antineurodegenerative properties on neuronal cells and tissues and that can be particularly used in the treatment and prophylaxis of neurodegenerative disease, particularly in the treatment and prophylaxis of Parkinson's disease is also disclosed. | 2022-04-28 |
20220127270 | PROCESSES FOR THE PREPARATION OF 4-{8-AMINO-3-[(2S)-1-(BUT-2-YNOYL)-PYRROLIDIN-2-YL]IMIDAZO[1,5-a]-PYRAZIN- -1-YL}N-(PYRIDIN-2-YL)-BENZAMIDE - The present disclosure relates, in general, to improved processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-2-yl)-benzamide, particularly large-scale processes for manufacturing 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-2-yl)benzamide and intermediates used in such processes. | 2022-04-28 |
20220127271 | NITROGEN-CONTAINING FUSED HETEROCYCLIC SHP2 INHIBITOR COMPOUND, PREPARATION METHOD, AND USE - Disclosed are a nitrogen-containing fused heterocyclic SHP2 inhibitor compound, a preparation method, and use. The nitrogen-containing fused heterocyclic SHP2 inhibitor compound is represented by formula I below. The compound has high inhibitory activity for an SHP2 enzyme and tumor cell proliferation, and has good druggability. | 2022-04-28 |
20220127272 | CXCR7 ANTAGONISTS - Compounds having formula I, | 2022-04-28 |
20220127273 | SALT OF ALDOSE REDUCTASE INHIBITOR, AND PREPARATION METHOD AND APPLICATION THEREOF - The present invention sets forth a salt of an aldose reductase inhibitor shown in formula A-N. The salt being able to be prepared as a crystal form, having notably improved solubility relative to the compound of formula A, having lower hygroscopicity allowing for stable existence, and thus being more easily made into a medicine than are the formula A compound or other salts. | 2022-04-28 |
20220127274 | MANUFACTURING PROCESS AND INTERMEDIATES FOR A PYRROLO[2,3-D]PYRIMIDINE COMPOUND AND USE THEREOF - The present invention relates to a manufacturing process and intermediates for preparing a crystalline or non-crystalline form of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide. The present invention also relates to salt forms and pharmaceutical compositions comprising the crystalline form, and to methods for use of the compound prepared from a crystalline form in the treatment of various diseases. | 2022-04-28 |
20220127275 | ETHYNYL DERIVATIVES - The present invention relates to compounds that may be used in the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression or diabetes type 2. | 2022-04-28 |
20220127276 | PYRAZINE DERIVATIVE AND APPLICATION THEREOF IN INHIBITING SHP2 - The present invention relates to a pyrazine derivative, an application thereof in inhibiting SHP2, and a compound of formula (I) or pharmaceutically acceptable salts, esters, isomers, solvates, prodrugs or isotope labels thereof. The structure of the compound of formula (I) is as follows. The novel pyrazine derivative provided by the present invention has excellent inhibition of SHP2 activity and can be used to prevent and/or treat non-receptor protein tyrosine phosphatase-mediated or dependent diseases or disorders. | 2022-04-28 |
20220127277 | ORGANIC COMPOUND FOR CAPPING LAYER AND ORGANIC LIGHT EMITTING DIODE COMPRISING THE SAME - As a compound for a capping layer for an organic light emitting device, disclosed is a capping layer compound represented by Formula 1 below. In addition, an organic light emitting device including the capping layer compound is also disclosed. | 2022-04-28 |
20220127278 | SYNTHESIS OF 14-METHYL-16-OXABICYCLO[10.3.1]HEXADEC-12-ENE - Disclosed is a scalable process for preparation of 14-methyl-16-oxabicyclo[10.3.1]hexadec-12-ene (BCE), a key intermediate for manufacture of fragrance ingredient 3-methylcyclopentadecenone (MUSCENONE®) and analogs through reaction of 3-Methyl-1,5-cyclopentadecanedione (MCPD) and analogs with a metal or metalloid alkoxide in high yield and purity. | 2022-04-28 |
20220127279 | MDM2-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE - The description relates to MDM2 binding compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the description provides compounds, which contain on one end a ligand which binds to the MDM2 E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type. | 2022-04-28 |
20220127280 | A SYNTHETIC NOVEL PYRROLOIMINOQUINONE ALKALOID AND METHOD OF USE - Aleutianamine represents the first in a new class of pyrroloiminoquinone alkaloids possessing a highly strained multi-bridged ring system, discovered from | 2022-04-28 |
20220127281 | HETEROARYL COMPOUNDS THAT INHIBIT G12C MUTANT RAS PROTEINS - The specification relates to compounds of Formula (I): | 2022-04-28 |
20220127282 | COMPOUNDS USEFUL TO TREAT INFLUENZA VIRUS INFECTIONS - The invention provides compounds that may inhibit influenza virus replication, and are accordingly useful for treatment of viral infections caused by influenza virus. The invention further provides pharmaceutical compositions containing these compounds and methods of using these compounds to treat or prevent viral infections caused by influenza virus. | 2022-04-28 |
20220127283 | POLYMORPHIC FORMS ALPHA, BETA AND GAMMA OF RIFAXIMIN - Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin α and rifaximin β, and a poorly crystalline form named rifaximin γ, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention. | 2022-04-28 |
20220127284 | BENZOTHIAZOLE DERIVATIVES AND 7-AZA-BENZOTHIAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF - The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be kinase (e.g., Janus kinase (JAK), e.g., Janus kinase 2 (JAK2)) inhibitors. Also provided are pharmaceutical compositions and kits including the provided compounds. Further provided are methods of using the provided compounds, pharmaceutical compositions, and kits (e.g., for treating a disease (e.g., proliferative disease) in a subject in need thereof). | 2022-04-28 |
20220127285 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES - The present invention relates to a compound of the formula (1), to the use of the compound in an electronic device, and to an electronic device comprising a compound of the formula (1). The present invention furthermore relates to a process for the preparation of a compound of the formula (1) and to a formulation comprising one or more compounds of the formula (1). | 2022-04-28 |
20220127286 | LIGANDS FOR NANO-SIZED MATERIALS - The present invention relates to a compound suitable as ligand for binding to the surface of a semiconductor nanoparticle, said compound comprising an anchor group, a linker group and an organic functional group; a semiconductor nanoparticle have said ligand attached to the outermost particle surface; a composition, a formulation and a process for the preparation of said semiconductor nanoparticle; and an electronic device. | 2022-04-28 |
20220127287 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE - An organometallic compound represented by Formula 1: | 2022-04-28 |
20220127288 | ORGANIC METAL COMPOUND, ORGANIC LIGHT EMITTING DIODE AND ORGANIC LIGHT EMITTING DEVICE HAVING THE COMPOUND - The present disclosure relates to an organic metal compound having the following structure of Formula 1, an organic light emitting diode (OLED) and an organic light emitting device that includes the organic metal compound. The OLED and the organic light emitting device including the organic metal compound can improve their luminous efficiency, luminous color purity and lifespan. | 2022-04-28 |
20220127289 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND - Provided are an organometallic compound represented by Formula 1, an organic light-emitting device including the organometallic compound, and a diagnostic composition including the organometallic compound. | 2022-04-28 |
20220127290 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE - An organometallic compound represented by Formula 1: | 2022-04-28 |
20220127291 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES - A compound having a structure of Formula I | 2022-04-28 |
20220127292 | METHOD FOR PRODUCING AMIDINATE METAL COMPLEX - To provide a method for producing an amidinate metal complex which is represented by [R | 2022-04-28 |
20220127293 | LIQUID METAL COMPLEX HAVING OXYGEN-ABSORBING ABILITY - To provide a liquid metal complex having an oxygen absorbing ability, containing a cobalt-acacen complex or a derivative thereof, and an ionic liquid in which an ionic ligand having an amine structure and a counter ion thereof are paired, in which the cobalt-acacen complex or the derivative thereof is expressed by general formula (1): | 2022-04-28 |
20220127294 | SELECTIVE ALKYLATION OF CYCLOPENTADIENE - Provided is a process for the mono-alkylation of cyclopentadiene, utilizing a cyclopentadiene magnesium halide and a metal salt of an alkyl or aryl sulfonate as co-reactant with an alkyl halide alkylating reactant. The process provides facile methodology for the mono-alkylation of cyclopentadiene, with conversions as high as about 96 percent and selectivity for mono-alkylation (over higher level alkylation, such as di- or tri-) as high as about 99%. | 2022-04-28 |
20220127295 | Method for lignin purification - The invention is directed to a method for producing a purified lignin salt from alkaline spent liquor from the chemical cooking of lignocellulosic raw materials. The method comprises the steps of decreasing the spent liquor pH to form a lignin precipitate suspension; filtering the lignin precipitate to form a lignin filter cake and a filtrate; mixing the lignin filter cake into a dilution liquid to form an alkalilignin agglomerate colloid; subjecting the alkalilignin agglomerate colloid to large-pore membrane filtration; and recovering a purified lignin salt concentrate. | 2022-04-28 |
20220127296 | PROCESS FOR PRODUCING AGGLOMERATED LIGNIN AND USE THEREOF - The present invention is directed to a process to produce agglomerated lignin with a controlled particle size distribution. The agglomerated lignin is essentially free of dust so that the risk of dust explosion is greatly reduced. | 2022-04-28 |
20220127297 | Novel Antibacterial 3"-Derivatives Of 4,6-Disubstituted 2,5-Dideoxystreptamine Aminoglycoside Antibiotics - The present invention relates to novel aminoglycoside compounds having antimicrobial properties and being suitable, for example, as therapeutic agents for use in the treatment of mammalian disease and in particular to novel therapeutic agents suitable for use in the treatment of microbial infection in mammals. The present invention further relates to the use of pharmaceutical compositions comprising said agents in the treatment of medical conditions in mammals, in particular in the treatment of microbial infection. The agents and pharmaceutical compositions of the invention are of particular relevance in the treatment of diseases associated with antibiotic-resistant microbes. The invention further relates to compounds for use in the treatment of diseases whose treatment is made otherwise difficult due to antibiotic-class-related bacterial resistance and provides novel therapeutic agents suitable for use in the treatment of multidrug-resistant (MDR) infections. | 2022-04-28 |
20220127298 | THERMOSPOROTHRIX HAZAKENSIS-DERIVED ANTIBACTERIALLY ACTIVE SUBSTANCE - This invention provides a novel compound having an antibacterial activity, and a method for producing the same. The compound is represented by Formula (I): | 2022-04-28 |
20220127299 | NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF - Disclosed herein, inter alia, are compounds, compositions, and methods of use thereof for sequencing a nucleic acid. | 2022-04-28 |
20220127300 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME - Disclosed are a 5′-modified nucleoside and a nucleotide using the same. The nucleoside of the present invention is represented by the formula (I) below. The 5′-modified nucleoside of the present invention is usable as a substitute for a phosphorothioate-modified nucleic acid, which has a risk of, for example, accumulation in a specific organ. The 5′-modified nucleoside also has excellent industrial productivity because a diastereomer separation step is not involved in the production process thereof. | 2022-04-28 |
20220127301 | ASYMMETRIC AUXILIARY GROUP - To provide a chiral reagent or a salt thereof. | 2022-04-28 |
20220127302 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF BILE ACID DERIVATIVES - The present disclosure relates to methods and novel intermediates useful in the preparation of a compound of formula I | 2022-04-28 |
20220127303 | THERAPEUTICALLY ACTIVE STEROIDAL DERIVATIVES - The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof | 2022-04-28 |
20220127304 | SEPARATING AGENT - Provided is a separating agent that does not have a significantly reduced dynamic binding capacity (DBC) to a target substance even when the separating agent is continually CIP-treated under alkaline pH conditions. The separating agent includes a carrier and a protein, wherein the protein is a given protein, and a surface of the carrier and a lysine residue in the protein are bound by a chemical bond. | 2022-04-28 |
20220127305 | MELANOCORTIN RECEPTOR LIGANDS - The present invention is directed to compounds according to formula, | 2022-04-28 |
20220127306 | PEPTIDE COMPOUNDS TO REGULATE THE COMPLEMENT SYSTEM - The present invention provides peptide compounds that regulate the complement system and methods of using these compounds. The invention is an isolated, purified peptide of 30 amino acids derived from human astrovirus protein, called CP1. The invention is directed to peptide compounds that are peptide mimetics, peptide analogs and/or synthetic derivatives of CP1 having, for example, internal peptide deletions and substitutions, deletions and substitutions at the N-terminus and C-terminus, and that are able to regulate complement activation. The invention further provides pharmaceutical compositions of therapeutically effective amounts of the peptide compounds and a pharmaceutically acceptable carrier, diluent, or excipient for treating a disease or condition associated with complement-mediated tissue damage. | 2022-04-28 |
20220127307 | ANTI-DENGUE VACCINES AND ANTIBODIES - A Dengue virus Envelope Dimer Epitope (EDE) wherein the EDE: c) spans the polypeptides of a Dengue virus Envelope polypeptide dimer; and/or d) is presented on a dimer of Envelope proteins; and/or c) is formed from consecutive or nonconsecutive residues of the envelope polypeptide dimer, wherein the dimer is a homodimer or heterodimer of native and/or mutant envelope polypeptides, from any one or two of DENV-1, DENV-2, DENV-3 and DENV-4. The EDE may be a stabilized recombinant dengue virus envelope glycoprotein E ectodomain (sE) dimer, wherein the dimer is: covalently stabilized with at least one disulphide inter-chain bond between the two sE monomers, and/or covalently stabilized with at least one sulfhydryl-reactive crosslinker between the two sE monomers, and/or covalently stabilized by linking the two sE monomers through modified sugars; and/or, covalently stabilised by being formed as a single polypeptide chain, optionally with a linker region, optionally a Glycine Serine rich linker region, separating the sE sequences, and/or non-covalently stabilized by substituting at least one amino acid residue in the amino acid sequence of at least one sE monomer with at least one bulky side chain amino acid, at the dimer interface or in domain 1 (D1)/domain 3 (D3) linker of each monomer. A compound, for example an antibody or antibody fragment that can neutralise more than one Dengue virus serotype, for example an antibody that can bind to an EDE of the invention. | 2022-04-28 |
20220127308 | Desmoglein 2 (DSG2) Binding Proteins and Uses Therefor - The present invention provides recombinant adenoviral compositions and methods for their use in treating disorders associated with epithelial tissues. | 2022-04-28 |
20220127309 | CHIMERIC MOLECULES AND USES THEREOF - Disclosed are chimeric polypeptides based on viral membrane fusion proteins. More particularly, the present invention discloses chimeric polypeptides that comprise a virion surface exposed portion of a viral fusion protein and a heterologous structure-stabilizing moiety, and to complexes of those chimeric polypeptides. The present invention also discloses the use of these complexes in compositions and methods for eliciting an immune response to a fusion protein of an enveloped virus, or complex of the fusion protein, and/or for treating or preventing an enveloped virus infection. The present invention further discloses the use of the heterologous structure-stabilizing moiety for oligomerizing heterologous molecules of interest. | 2022-04-28 |
20220127310 | MUTANT AEROLYSIN AND USES THEREOF - Aerolysin polypeptides and/or mutant aerolysin monomers include modified amino acid sequences that could have improved substrate analyte, such as (poly)nucleotide and peptide, improved reading properties such as enhanced substrate analyte capture and improved substrate analyte recognition and/or discrimination. Also, aerolysin pores may be derived from the mutant monomers as well as apparatuses and devices may include modified aerolysin polypeptides. Further, methods of using modified aerolysin proteins and pores derive therefrom may be used in characterizing and/or sequencing a polymeric molecule or may be for use as molecular sensors. | 2022-04-28 |
20220127311 | CELL FACTORIES FOR IMPROVED PRODUCTION OF COMPOUNDS AND PROTEINS DEPENDENT ON IRON SULFUR CLUSTERS - The invention relates to a genetically modified prokaryotic cell capable of improved iron-sulfur cluster delivery, characterized by a modified gene encoding a mutant Iron Sulfur Cluster Regulator (IscR) and one or more transgenes or upregulated endogenous genes encoding iron-sulfur (Fe—S) cluster polypeptides or proteins that catalyze complex radical-mediated molecular rearrangements, electron transfer, radical or non-redox reactions, sulfur donation or perform regulatory functions. The prokaryotic cells are characterized by enhanced activity of these iron-sulfur (Fe—S) cluster polypeptides, enhancing their respective functional capacity, and facilitating enhanced yields of compounds in free and protein-bound forms, including heme, hemoproteins, tetrapyrroles, B vitamins, amino acids, δ-aminolevulinic acid, biofuels, isoprenoids, pyrroloquinoline quinone, ammonia, indigo, or their precursors, whose biosynthesis depends on their activity. The invention further relates to a method for producing said compounds or their precursors using the genetically modified prokaryotic cell of the invention, and the use of the genetically modified prokaryotic cell. | 2022-04-28 |
20220127312 | NOVEL FOLR1 SPECIFIC BINDING PROTEINS FOR CANCER DIAGNOSIS AND TREATMENT - The present invention relates to new binding proteins that are specific for folate receptor alpha (FOLR1). The invention further refers to FOLR1 binding proteins that further comprises a diagnostically or therapeutically active component. Further aspects of the invention cover the use of these FOLR1 binding proteins in medicine, for example, in diagnosis and therapy of FOLR1 related cancer. | 2022-04-28 |
20220127313 | POLYPEPTIDES FOR RESTORING ENDOTHELIAL FUNCTION AND METHODS OF USE THEREOF - The present disclosure provides novel cell permeant polypeptides and pharmaceutical compositions thereof, and methods for using such polypeptides and pharmaceutical compositions for various therapeutic uses. The present disclosure more specifically provides polypeptides for restoring endothelial function. | 2022-04-28 |
20220127314 | LEUCINE-RICH ALPHA2 GLYCOPROTEIN COMPOSITION - An object is to provide a leucine-rich α2 glycoprotein composition comprising leucine-rich α2 glycoprotein and having excellent preservation stability. The object can be achieved by a leucine-rich α2 glycoprotein composition comprising leucine-rich α2 glycoprotein and having a pH of 7.0 to 9.3. | 2022-04-28 |
20220127315 | GIPR-AGONIST COMPOUNDS - The present invention relates to compounds having activity at the human glucose-dependent insulinotropic polypeptide (GIP) receptor. The present invention also relates to compounds having an extended duration of action at the GIP receptor. Such compounds may be useful in the treatment of diabetes, including type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity. | 2022-04-28 |
20220127316 | Peptide Ligands of the Gdnf Family Receptor A-Like (Gfral) Receptor - The present invention relates to engineered peptides and to methods of making engineered peptides. The present invention also relates to methods of treatment comprising administration of the engineered peptides to a subject in need thereof. | 2022-04-28 |
20220127317 | ANTITUMOR CELL COMPRISING A CHARGE MODIFIED GLOBIN - There is provided an antitumour cell, liposome or micelle, comprising at least one charge-modified globin associated with the membrane of the cell, liposome or micelle, and methods of making and using the same. | 2022-04-28 |
20220127318 | RECOMBINANT LUBRICINS, AND COMPOSITIONS AND METHODS FOR USING THE SAME - Provided are compositions and methods related to modified lubricins, methods of making the modified lubricins, and methods of using the modified lubricins for coating a variety of inanimate objects, and for prophylaxis and/or therapy of disorders where enhanced lubrication of one or more parts of a human or non-human mammal is desirable. | 2022-04-28 |
20220127319 | RECOMBINANT MUCINS, AND COMPOSITIONS AND METHODS FOR USING THE SAME - Provided are compositions and methods related to improved mucins, methods of making the improved mucins, and cells and cell cultures that express glycosylated mucins. The compositions and methods provide improved cell cultures, and improved methods of producing co-expressed proteins that are distinct from the mucins. | 2022-04-28 |
20220127320 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2022-04-28 |
20220127321 | ANTIBODY CYTOKINE ENGRAFTED COMPOSITIONS AND METHODS OF USE FOR IMMUNOREGULATION - The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through interleukin 10 receptor. Provided antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prophylaxis of immune related disorders. Additionally provided are polynucleotides and vectors that encode antibody cytokine engrafted proteins and host cells capable of producing antibody cytokine engrafted proteins, as well as methods of combining antibody cytokine engrafted proteins with other therapeutics in treating immune related disorder. | 2022-04-28 |
20220127322 | DUAL-TARGET FUSION PROTEINS COMPRISING THE FC PORTION OF AN IMMUNOGLOBULIN - Provided is a fusion protein containing GLP-1 and FGF21 linked through an immunoglobulin Fc portion. Each of the GLP-1 and FGF21 can be substituted with its analogues or variants and, the Fc portion, which can be derived from IgG4, can include substitutions that further enhance the fusion protein's stability and activity. These fragments can be linked together through peptide linkers. The fusion protein can be used clinically to reduce glucose and lipid levels and body weight. | 2022-04-28 |
20220127323 | NOVEL POLYPEPTIDE AND THERAPEUTIC USES THEREOF - The invention relates to the field of peptide chemistry, in particular, the invention relates to a peptide compound and its use in medical treatment. | 2022-04-28 |
20220127324 | METHOD FOR CONTINUOUS PRODUCTION OF RECOMBINANT GLP-1 PEPTIDE BY BACTERIA - The invention relates to a method for continuously producing and secreting recombinant Glucagon-like peptide-1 (GLP-1) by bacteria, more specifically | 2022-04-28 |
20220127325 | GLUCAGON DERIVATIVE AND A COMPOSITION COMPRISING A LONG ACTING CONJUGATE OF THE SAME - A glucagon derivative, a long-acting conjugate of the glucagon derivative, and a use thereof are disclosed. | 2022-04-28 |
20220127326 | Targeted Therapeutic Lysosomal Enzyme Fusion Proteins and Uses Thereof - The present invention relates in general to therapeutic fusion proteins useful to treat lysosomal storage diseases and methods for treating such diseases. Exemplary therapeutic fusion proteins comprise a lysosomal enzyme, a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. Also provided are compositions and methods for treating Mucopolysaccharidosis Type IIIB (Sanfilippo B Syndrome), comprising a targeted therapeutic fusion protein comprising alpha-N-acetylglucosaminidase (Naglu), a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. | 2022-04-28 |
20220127327 | T CELL RECEPTORS - The present invention relates to T cell receptors (TCRs) which bind the HLA-A*0201 restricted peptide GVYDGEEHSV (SEQ ID NO: 1) derived from the MAGE-B2 protein. The TCRs of the invention demonstrate excellent specificity profiles for this MAGE epitope. Also provided are nucleic acids encoding the TCRs, cells engineered to present the TCRs, cells harbouring expression vectors encoding the TCRs and pharmaceutical compositions comprising the TCRs, nucleic acids or cells of the invention. | 2022-04-28 |
20220127328 | IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS - Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies. | 2022-04-28 |
20220127329 | ALTERNATIVE INTRACELLULAR SIGNALLING DOMAIN OF A CHIMERIC ANTIGEN RECEPTOR - The present invention relates to the field of biotechnology, specifically to an isolated alternative intracellular signalling domain of a chimeric antigen receptor (CAR) and to a chimeric antigen receptor (CAR) comprising, said signalling domain. The invention also relates to a nucleic acid coding an alternative intracellular signalling domain of a chimeric antigen receptor, and to a nucleic acid coding a chimeric antigen receptor with the above-mentioned signalling domain, to an expression vector, to a delivery vector, and also a genetically modified cell which comprises the above-mentioned chimeric antigen receptor, and to a method for producing said cell. | 2022-04-28 |
20220127330 | BMP-ALK3 ANTAGONISTS AND USES FOR PROMOTING BONE GROWTH - In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density and strength. In certain embodiments, the present invention provides ALK3 polypeptides, including ALK3-Fc fusion proteins. | 2022-04-28 |
20220127331 | METHODS FOR PRODUCING AFLIBERCEPT IN CHEMICALLY DEFINED MEDIA HAVING REDUCED AFLIBERCEPT VARIANTS - The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions. | 2022-04-28 |
20220127332 | MULTI-FUNCTIONAL AND MULTI-VALENT INTERLEUKIN-TGF-BETA RECEPTOR FUSION POLYPEPTIDES - Provided are multi-functional and multi-valent fusion polypeptides comprising an interleukin polypeptide and two or more TGFβ ligand-binding polypeptides. The compositions and methods provided herein are useful in the application of preventing tumorigenesis and treating cancer. | 2022-04-28 |
20220127333 | RECOMBINANT ELASTIN AND PRODUCTION THEREOF - This disclosure provides non-naturally occurring truncated elastin molecules. The non-naturally occurring truncated elastin may improve the firmness, elasticity, brightness, hydration, tactile texture, and/or visual texture of skin. The non-naturally occurring truncated elastin may reduce degradation of the extracellular matrix. | 2022-04-28 |
20220127334 | UTI FUSION PROTEINS - The present invention provides UTI fusion proteins, DNA sequences for producing the same, and pharmaceutical compositions and methods of using the same. | 2022-04-28 |
20220127335 | TETRAMERIC PROTEIN SCAFFOLDS AS NANO-CARRIERS OF THERAPEUTIC PEPTIDES FOR TREATING CANCER AND OTHER DISEASES - A protein-based peptide drug carrier derived from the tetramerization domain of the chimeric oncogenic protein Bcr/Abl of chronic myeloid leukemia. Peptides to be delivered are grafted to the N-terminal helical region of Bcr/Abl tetramer. To facilitate cellular uptake, an Arg-repeating hexapeptide is added to the C-terminal end of the Bcr/Abl protein. The protein-based delivery strategy provides a clinically viable solution to p53-inspired anticancer therapy and is applicable to the development of many other peptide therapeutics to target other intracellular protein-protein interactions responsible for disease initiation and progression. | 2022-04-28 |
20220127336 | ANTIBODIES THAT NEUTRALIZE HEPATITIS B VIRUS AND USES THEREOF - The present disclosure relates to antibodies, and antigen binding fragments thereof, that can bind to the antigenic loop region of hepatitis B surface antigen (HBsAg) and can neutralize infection of both hepatitis B virus (HBV) and hepatitis delta virus (HDV). The present disclosure also relates to epitopes to which the antibodies and antigen binding fragments bind, as well as to fusion proteins that comprise the antigen binding fragments, and to nucleic acids that encode and cells that produce such antibodies and antibody fragments. In addition, the present disclosure relates to the use of the antibodies and antibody fragments of the present disclosure in the diagnosis, prophylaxis and treatment of hepatitis B and hepatitis D. | 2022-04-28 |
20220127337 | Anti-Viroporin Antibodies and Methods of Treating COVID-19 - Described are methods for generating human antibodies capable of blocking one or more functions of coronavirus viroporins. The methods can be used to generate therapeutic antibodies to treat or prevent coronavirus infection, including SARS-CoV-2 infection. | 2022-04-28 |
20220127338 | DECREASING STAPHYLOCOCCUS AUREUS INFECTIONS IN COLONIZED PATIENTS - The present disclosure is directed to methods of treating subjects colonized with | 2022-04-28 |
20220127339 | STREPTOCOCCUS PNEUMONIAE ANTISERUM WITHOUT CROSS-REACTIVITY AND METHOD FOR PRODUCING THE SAME - The present invention relates to a | 2022-04-28 |
20220127340 | ASPERGILLUS ANTIGEN CHIMERIC RECEPTORS AND USE THEREOF - Provided herein is an antibody as well as chimeric antigen receptor (CAR) to the | 2022-04-28 |
20220127341 | A METHOD FOR THE TREATMENT OR PROPHYLAXIS OF CANCER BY TARGETING THE EXTRACELLULAR PORTION OF KERATIN 14 (KRT14) RESIDING ON CANCER CELLS - Disclosed herein are methods, uses and compositions for the treatment or prophylaxis of cancer in a mammalian subject comprising administering to the subject an amount of an agent which targets an extracellular portion of KRT14 or its functional homolog or variant thereof resident on cancer cells or an agent which induces production of an antagonist of the extracellular portion of KRT14 or its functional homolog or variant on cancer cells. The present disclosure also extends to methods of monitoring and/or diagnosing cancer in a subject. | 2022-04-28 |
20220127343 | Antigen Binding Regions Against Fibronectin Type III Domains and Methods of Using the Same - Fibronectin type III (FN3) domain antibodies, polynucleotides capable of encoding the FN3 domain antibodies or antigen-binding fragments, cells expressing FN3 domain antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled FN3 domain antibodies or antigen-binding fragments may be used to engineer FN3 domain-targeting chimeric antigen receptors (CARs). Methods of making the FN3 domain antibodies, CARs, and engineered immune cells, and methods of using the engineered immune cells are applicable to treat diseases including cancer. | 2022-04-28 |
20220127344 | ANTI-SEMA3A ANTIBODIES AND THEIR USES FOR TREATING A THROMBOTIC DISEASE OF THE RETINA - The invention relates to the use of antibodies and antibody that target semaphorin 3A (Sema3A), and fragments thereof, and their use for treating thrombotic diseases of the retina comprising. | 2022-04-28 |
20220127345 | Methods of Reducing Tau in Human Subjects - Methods are described for reducing tau in a subject. The methods involve administering to a subject an anti-tau antibody that binds to tau, in particular that bind to a phosphorylated epitope on tau. The methods may be used to reduce p217+tau in CSF, including total p217+tau and free p217+tau. | 2022-04-28 |
20220127346 | Methods of Safe Administration of Anti-Tau Antibody - Methods are described for safely administering to a subject in need thereof an anti-tau antibody that bind to tau, in particular that bind to a phosphorylated epitope on tau. The methods comprise administering a pharmaceutical composition comprising the anti-tau antibody, in which the anti-tau antibody is administered in an amount of about 500 mg to 5000 mg per dose. | 2022-04-28 |
20220127347 | Inhibition of Tau Propagation - Provided are novel methods of inhibiting the propagation of pathological forms of tau between cells of the central nervous system by administration of an inhibitor of LRP1. LRP1 was discovered to facilitate the endocytosis of pathological forms of tau which enables the propagation of tau aggregates and resulting neurodegeneration. These methods enable the prevention and treatment of various tauopathies, such as Alzheimer's, chronic traumatic encephalopathy, corticobasal degeneration, and others. | 2022-04-28 |
20220127348 | METHODS FOR TREATING HYPERLIPIDEMIA WITH AN ANGPTL8 INHIBITOR AND AN ANGPTL3 INHIBITOR - The present invention provides methods for treating patients suffering from hyperlipidemia, wherein the patient is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to angiopoietin-like protein 8 (ANGPTL8) in combination with a therapeutically effective amount of an antibody that specifically binds to angiopoietin-like protein 3 (ANGPTL3). The combination of an anti-ANGPTL8 antibody with an anti-ANGPTL3 antibody is useful in treating diseases such as hypercholesterolemia, including familial hypercholesterolemia (FH), both heFH and hoFH, as well as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, chylomicronemia, and to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor, such as cardiovascular diseases. | 2022-04-28 |
20220127349 | ANTIBODIES WITH REDUCED IMMUNOGENICITY - Methods of reducing immunogenicity of an antibody are provided, as are methods of producing a second antibody from a first. Polypeptide and antibody sequences are also provided. | 2022-04-28 |
20220127350 | MULTISPECIFIC ANTIBODIES HAVING SPECIFICITY FOR TNFA AND IL-17A, ANTIBODIES TARGETING IL-17A, AND METHODS OF USE THEREOF - The present invention relates to an isolated multispecific antibody comprising a first domain specifically binding TNFα and a second domain specifically binding IL-17A and, optionally, a third domain specifically binding human serum albumin. The present invention furthermore relates to an isolated antibody which specifically binds human IL-17A, Additionally, the present invention further relates to methods of use of said antibodies, pharmaceutical compositions and methods of use thereof, and a kit comprising said antibodies. The present invention also relates to a nucleic acid comprising a nucleotide sequence encoding said antibodies, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said antibodies. | 2022-04-28 |
20220127351 | INTERLEUKIN-31 MONOCLONAL ANTIBODIES FOR VETERINARY USE - A monoclonal antibody, or antigen-binding portion thereof is provided that specifically binds to a region on a mammalian IL-31 protein involved with interaction of the IL-31 protein with its co-receptor, wherein the binding of said antibody to said region is impacted by mutations in a 15H05 epitope binding region selected from: a region between about amino acid residues 124 and 135 of a feline IL-31 sequence represented by SEQ ID NO: 157 (Feline_IL31_wildtype); a region between about amino acid residues 124 and 135 of a canine IL-31 sequence represented by SEQ ID NO: 155 (Canine_IL31); and a region between about amino acid residues 118 and 129 of an equine IL-31 sequence represented by SEQ ID NO: 165 (Equine_IL31). Such antibodies can be in the form of veterinary compositions useful for treating IL-31-mediated disorders in cats, dogs, or horses. | 2022-04-28 |
20220127352 | ANTIBODIES THAT SPECIFICALLY BIND TO HUMAN IL-15 AND USES THEREOF - Recombinant antibodies that specifically bind to IL-15 as well as a complex of IL-15 and the IL-15 Receptor-alpha are provided. The antibodies inhibit immune cell proliferation, and are capable of use in the treatment of any autoimmune or inflammatory disease or condition where IL-15 is dysregulated, including Celiac disease. | 2022-04-28 |
20220127353 | TREATMENT OF HIDRADENITIS SUPPURATIVA - Hidradenitis suppurativa can be treated by administering a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1α. | 2022-04-28 |
20220127354 | ANTIBODIES TARGETING CDH19 FOR MELANOMA - The present disclosure provides a human antibody or antigen binding fragment thereof or an antibody construct comprising a human binding domain or antigen binding fragment thereof capable of binding to human CDH19 on the surface of a target cell. The disclosure relates to a nucleic acid sequence encoding the antibody or antigen binding fragment thereof contained in the antibody construct, a vector comprising the nucleic acid sequence and a host cell transformed or transfected with the vector. Furthermore, the disclosure relates to a process for the production of the antibody construct of the disclosure, a medical use or a method of treatment using the antibody construct and a kit comprising the antibody or antigen binding fragment thereof or the antibody construct. | 2022-04-28 |
20220127355 | CLAUDIN 6 ANTIBODIES AND USES THEREOF - Antibodies and compositions against Claudin 6 and uses thereof are provided. | 2022-04-28 |
20220127356 | TREM2 ANTIBODIES AND USES THEREOF - The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human Triggering Receptor Expressed on Myeloid Cells 2 (TREM2). The anti-TREM2 antibodies or antigen-binding fragments thereof are useful, for example, in detecting TREM2 and in treating neurodegenerative diseases. | 2022-04-28 |
20220127357 | ANTI-CD47 ANTIBODIES AND USES THEREOF - Provided are anti-CD47 antibodies and fragments thereof. The antibodies and fragments thereof specifically bind to the CD47 protein. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and atherosclerosis are also provided. | 2022-04-28 |
20220127358 | HUMANIZED ANTIBODIES AGAINST C-KIT - The invention provides antibodies specifically binding to c-Kit and methods of using such antibodies in stem cell replacement and treatment of cancer. | 2022-04-28 |
20220127359 | ANTI-VBETA17/ANTI-CD123 BISPECIFIC ANTIBODIES - The present disclosure relates to Vβ17/CD123 bispecific antibodies. The antibodies are characterized by their CDRs sequences. Toxicity experiments are performed on Kasumi-3 cells (used to perform acute myeloblastic leukaemia pathologies) | 2022-04-28 |
20220127360 | TETRAVALENT BISPECIFIC ANTIBODY AGAINST PD-1 AND VEGF, PREPARATION METHOD THEREFOR, AND USE THEREOF - Provided are a structurally symmetrical tetravalent bispecific antibody based on a common light chain and a construction method therefor. The prepared tetravalent bispecific antibody has similar or even better biological activity and physical and chemical properties than monoclonal antibodies, and can be used for the treatment of various inflammatory diseases, cancer, and other diseases. | 2022-04-28 |
20220127361 | TETRAVALENT BISPECIFIC ANTIBODY AGAINST PD-1/TGF-beta, PREPARATION METHOD THEREFOR, AND USE THEREOF - Provided are a structurally symmetrical tetravalent bispecific antibody based on a common light chain and a construction method therefor. The prepared tetravalent bispecific antibody has similar or even better biological activity and physical and chemical properties than monoclonal antibodies, and can be used for the treatment of various inflammatory diseases, cancer, and other diseases. | 2022-04-28 |
20220127362 | TETRAVALENT BISPECIFIC ANTIBODY AGAINST PD-1/LAG-3, PREPARATION METHOD THEREFOR, AND USE THEREOF - Provided are a structurally symmetrical tetravalent bispecific antibody based on a common light chain and a construction method therefor. The prepared tetravalent bispecific antibody has similar or even better biological activity and physical and chemical properties than monoclonal antibodies, and can be used for the treatment of various inflammatory diseases, cancer, and other diseases. | 2022-04-28 |
20220127363 | USE OF ANTI-CTLA-4 ANTIBODIES WITH ENHANCED ADCC TO ENHANCE IMMUNE RESPONSE TO A VACCINE - The present invention provides methods of enhancing immune response to a vaccine using variant forms of anti-CTLA-4 antibodies having enhanced ADCC activity. Variant anti-CTLA-4 antibodies for use in the present invention include nonfucosylated ipilimumab. | 2022-04-28 |